

Contents

Preface

V

A Personal Foreword

VII

1	Introduction	1
1.1	Modern History of Molecular Modeling	2
1.2	Do Today's Molecular Modeling Methods Illustrate only the Lukretian World?	3
1.3	What are Models Used for?	4
1.4	Molecular Modeling Uses All Four Types for Model Building	4
1.5	The Final Step is <i>Design</i>	4
1.6	The Scope of the Book	5
2	Small Molecules	9
2.1	Generation of 3D Coordinates	9
2.1.1	Crystal Data	9
2.1.2	Fragment Libraries	10
2.1.3	Sketch Approach	12
2.2	Computational Tools for Geometry Optimization	13
2.2.1	Force Fields	13
2.2.2	Geometry Optimization	15
2.2.3	Energy-Minimizing Procedures	16
2.2.3.1	Steepest Descent Minimizer	17
2.2.3.2	Conjugate Gradient Method	17
2.2.3.3	Newton-Raphson Minimizer	17
2.2.4	Use of Charges, Solvation Effects	18
2.2.5	Quantum Mechanical Methods	19
2.2.5.1	Ab initio Methods	19
2.2.5.2	Semiempirical Molecular Orbital Methods	21
2.3	Conformational Analysis	23
2.3.1	Conformational Analysis Using Systematic Search Procedures	25
2.3.2	Conformational Analysis Using Monte Carlo Methods	29
2.3.3	Conformational Analysis Using Molecular Dynamics	29

2.4	Determination of Molecular Interaction Potentials	37
2.4.1	Molecular Electrostatic Potentials (MEPs)	37
2.4.1.1	Methods for Calculating Atomic Point Charges	38
2.4.1.2	Methods for Generating MEPs	42
2.4.2	Molecular Interaction Fields	43
2.4.2.1	Calculation of GRID Fields	45
2.4.2.2	How GRID Fields can be Exploited	47
2.4.2.3	Use of Chemometrics: The CoMFA Method	49
2.4.3	Hydrophobic Interactions	49
2.4.3.1	Log <i>P</i> as a Measure of Lipophilicity	50
2.4.3.2	The Hydropathic Field	50
2.4.3.3	Display of Properties on a Molecular Surface	51
2.5	Pharmacophore Identification	55
2.5.1	Molecules to be Matched	55
2.5.2	Atom-by-Atom Superposition	56
2.5.3	Superposition of Molecular Fields	58
2.6	The Use of Data Bants	60
2.6.1	Conversion of 2D Structural Data into 3D Form	60
2.6.2	3D Searching	61
3	Example for Small Molecule Modeling: Serotonin Receptor Ligands	65
3.1	Definition of the Serotonergic Pharmacophore	65
3.2	The Molecular Interaction Field	69
3.3	Construction of a 5-HT _{2a} Receptor Binding Site Model	71
3.4	Calculation of Interaction Energies	73
3.5	Validation of the Model	74
4	Introduction to Protein Modeling	77
4.1	Where and How to get Information on Proteins	77
4.2	Terminology and Principles of Protein Structure	81
4.2.1	Conformational Properties of Proteins	81
4.2.2	Types of Secondary Structural Elements	84
4.2.2.1	The α -Helix	84
4.2.2.2	The β -Sheet	85
4.2.2.3	Turns	87
4.2.3	Homologous Proteins	88
4.3	Knowledge-Based Protein Modeling	91
4.3.1	Procedures for Sequence Alignments	92
4.3.2	Determination and Generation of Structurally Conserved Regions (SCRs)	96
4.3.3	Construction of Structurally Variable Regions (SVRs)	98
4.3.4	Side Chain Modeling	99

4.3.5	Distance Geometry Approach	101
4.3.6	Secondary Structure Prediction	101
4.3.7	Energy-Based Modeling Methods	103
4.4	Optimization Procedures — Model Refinement — Molecular Dynamics . . .	109
4.4.1	Force Fields for Protein Modeling	109
4.4.2	Geometry Optimization	110
4.4.3	The Use of Molecular Dynamics Simulations in Model Refinement	111
4.4.4	Treatment of Solvated Systems	113
4.4.5	Ligand-Binding Site Complexes	113
4.5	Validation of Protein Models	115
4.5.1	Stereochemical Accuracy	116
4.5.2	Packing Quality	120
4.5.3	Folding Reliability	122
4.6	Properties of Proteins	127
4.6.1	Electrostatic Potential	127
4.6.2	Interaction Potentials	130
4.6.3	Hydrophobicity	130
5	Example for the Modeling of Protein–Ligand Complexes:	
	Antigen Presentation by MHC Class I	133
5.1	Biochemical and Pharmacological Description of the Problem	133
5.1.1	Antigenic Proteins are Presented as Nonapeptides	134
5.1.2	Pharmacological Target: Autoimmune Reactions	134
5.2	Molecular Modeling of the Antigenic Complex	
	Between a Viral Peptide and a Class I MHC Glycoprotein	135
5.2.1	Modeling of the Ligand	135
5.2.2	Homology Modeling of the MHC Protein	136
5.2.2.1	Preparation of the Coordinates	137
5.2.2.2	Building the H-2L ^d Molecule	137
5.3	Molecular Dynamics Studies of MHC-Peptide Complexes	146
5.3.1	HLA-A2 — The Fate of the Complex during	
	Molecular Dynamics Simulations	146
5.3.2	HLS-B*2705	148
5.3.2.1	The Fate of the Complex during Molecular Dynamics Simulations	150
5.4	Analysis of Models that Emerged from	
	Molecular Dynamics Simulations	153
5.4.1	Hydrogen Bonding Network	153
5.4.2	Atomic Fluctuations	154
5.4.3	Solvent-Accessible Surface Areas	157
5.4.4	Interaction Energies	158
5.5	SAR of the Antigenic Peptides from Molecular	
	Dynamics Simulations and Design of Non-natural Peptides	
	as High-Affinity Ligands for a MHC I Protein	160

5.5.1	The Design of New Ligands	160
5.5.2	Experimental Validation of the Designed Ligand	163
5.6	Summary and Conclusion	164

Appendices	165
-----------------------------	-----

Index	177
------------------------	-----

1.1	Use of Chemometrics: The CoMFA Method	414
1.2	Hydrophobic Interactions	415
1.2.1	Log <i>P</i> as a Measure of Lipophilicity	415
1.2.2	The Hydrophobic Field	415
1.2.3	Display of Properties on a Molecular Surface	415
1.3	Pharmacophore Identification	415
1.4	Molecules to be Matched	415
1.5	Atom-by-Atom Superposition	415
1.6	Superposition of Molecular Fields	415
1.7	The Use of Data Banks	415
1.8	Conversion of 2D Structural Data into 3D Form	415
1.9	3D Searching	415
2	Antigen Presentation by MHC Class I	415
2.1	Example for Small Molecule Models	415
2.2	Biochemical and Pharmacological Description of the Tryptophan Receptor	415
2.3	Antigenic Proteins are Presented as Nonapeptides	415
2.4	Pharmacological Target: Antigenic Receptors and Antagonists	415
2.5	Molecular Modeling of the Antigenic Complex	415
2.6	Between a Viral Peptide and a Class I MHC Glycoprotein	415
2.7	Modeling of the Ligand	415
2.8	Homology Modeling of the MHC Protein	415
2.9	Preparation of the Coordinates	415
2.10	Building the H-2L ^b Molecule	415
2.11	Molecular Dynamics Studies of MHC-Peptide Complexes	415
2.12	HLA-A2—The Fate of the Complex during Antigen Presentation	415
2.13	Molecular Dynamics Simulations of Antigen Presentation	415
2.14	Conformational Properties of Proteins	415
2.15	The Fate of the Complex during Antigen Presentation	415
2.16	Analysis of Models that Emerged from	415
2.17	Molecular Dynamics Simulations	415
2.18	Hydrogen Bonding Network	415
2.19	Atomic Fluctuations	415
2.20	Solvent-Accessible Surface Areas	415
2.21	Interaction Energies	415
2.22	SAO of the Antigenic Peptide	415
2.23	Dynamics Simulations and Design of Non-peptide Ligands	415
2.24	as High-Affinity Ligands for a MHC I Protein	415